Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 8,058 Shares of Pfizer Inc. (NYSE:PFE)

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 19.9% during the 1st quarter, HoldingsChannel reports. The fund owned 32,453 shares of the biopharmaceutical company’s stock after selling 8,058 shares during the period. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Pfizer were worth $901,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. GoalVest Advisory LLC lifted its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter worth about $32,000. Trivant Custom Portfolio Group LLC grew its position in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. VisionPoint Advisory Group LLC increased its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer during the fourth quarter worth about $36,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $35.54.

Pfizer Stock Up 0.6 %

Pfizer stock traded up $0.18 during mid-day trading on Friday, reaching $27.98. The stock had a trading volume of 33,189,215 shares, compared to its average volume of 34,031,364. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.80. The stock’s 50-day simple moving average is $27.90 and its 200-day simple moving average is $27.68. The firm has a market capitalization of $158.55 billion, a PE ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the firm earned $1.23 earnings per share. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.